Metformin Accord

Metformin Hydrochloride, the active ingredient in Metformin Accord, is a biguanide presented as a tablet for oral use. It is used to improve blood glucose control in adults with type 2 diabetes mellitus. GNH USA supplies Metformin Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metformin Accord belongs to the biguanide class and is employed to manage disorders of glucose metabolism. - Type 2 diabetes mellitus: lowers fasting and post‑prandial blood glucose levels. - Prediabetes (impaired glucose tolerance): helps delay progression to overt diabetes. - Insulin resistance associated conditions: improves peripheral insulin sensitivity and reduces hepatic glucose output.

Metformin is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: frequent loose stools, especially during treatment initiation. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Weight loss: modest reduction in body weight. - Vitamin B12 deficiency: decreased absorption with long‑term use.

Serious or Rare Side Effects: - Lactic acidosis: life‑threatening metabolic acidosis, especially in renal impairment. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Hypoglycaemia: when combined with other glucose‑lowering agents. - Anemia: hemolytic or aplastic in rare cases. - Renal impairment: acute kidney injury secondary to accumulation.

Metformin should be used with careful clinical monitoring to minimise risks. - Renal function assessment: evaluate creatinine clearance before initiation and periodically thereafter. - Hepatic function monitoring: avoid use in patients with significant liver disease. - Lactic acidosis risk: discontinue before any procedure requiring iodinated contrast or in cases of acute illness. - Vitamin B12 monitoring: consider periodic testing during long‑term therapy. - Contraindication in severe renal impairment: do not use when eGFR is below 30 mL/min/1.73 m². - Pregnancy and lactation: assess risk‑benefit ratio; use only if clearly needed. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Metformin may interact with several medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Iodinated contrast agents: increase risk of lactic acidosis; suspend metformin before and after exposure. - Alcohol: potentiates lactic acidosis, especially with chronic intake. - Cimetidine: can raise metformin plasma concentrations. - Other biguanides: additive risk of lactic acidosis.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors or ARBs: may affect renal function, requiring dose adjustment. - Thiazide diuretics: can increase blood glucose levels. - NSAIDs: may impair renal clearance of metformin. - CYP450 inhibitors (e.g., fluoroquinolones): modestly raise metformin levels.